Navamedic Past Earnings Performance
Past criteria checks 0/6
Navamedic has been growing earnings at an average annual rate of 45%, while the Pharmaceuticals industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 24.3% per year.
Key information
45.0%
Earnings growth rate
72.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 24.3% |
| Return on equity | -4.8% |
| Net Margin | -2.1% |
| Next Earnings Update | 16 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Navamedic makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 511 | -11 | 151 | 0 |
| 31 Dec 23 | 512 | 4 | 147 | 0 |
| 30 Sep 23 | 503 | 24 | 80 | 0 |
| 30 Jun 23 | 454 | 20 | 56 | 0 |
| 31 Mar 23 | 441 | 43 | 57 | 0 |
| 31 Dec 22 | 382 | 29 | 48 | 0 |
| 30 Sep 22 | 356 | 12 | 59 | 0 |
| 30 Jun 22 | 327 | 8 | 47 | 0 |
| 31 Mar 22 | 283 | 4 | 49 | 0 |
| 31 Dec 21 | 278 | 1 | 44 | 0 |
| 30 Sep 21 | 244 | -7 | 50 | 0 |
| 30 Jun 21 | 237 | -6 | 38 | 0 |
| 31 Mar 21 | 213 | -8 | 46 | 0 |
| 31 Dec 20 | 210 | -16 | 33 | 0 |
| 30 Sep 20 | 202 | -22 | 58 | 0 |
| 30 Jun 20 | 194 | -24 | 33 | 0 |
| 31 Mar 20 | 199 | -26 | 34 | 0 |
| 31 Dec 19 | 189 | -16 | 33 | 0 |
| 30 Sep 19 | 193 | -1 | 32 | 0 |
| 30 Jun 19 | 189 | 0 | 27 | 0 |
| 31 Mar 19 | 187 | 10 | 25 | 0 |
| 31 Dec 18 | 184 | 4 | 26 | 0 |
| 30 Sep 18 | 177 | -20 | 30 | 0 |
| 30 Jun 18 | 178 | -13 | 28 | 0 |
| 31 Mar 18 | 222 | -20 | 30 | 0 |
| 31 Dec 17 | 258 | -16 | 30 | 0 |
| 30 Sep 17 | 294 | 3 | 31 | 0 |
| 30 Jun 17 | 315 | 4 | 32 | 0 |
| 31 Mar 17 | 292 | -9 | 31 | 0 |
| 31 Dec 16 | 274 | -11 | 31 | 0 |
| 30 Sep 16 | 258 | -28 | 31 | 0 |
| 30 Jun 16 | 254 | -30 | 30 | 0 |
| 31 Mar 16 | 247 | -17 | 28 | 0 |
| 31 Dec 15 | 248 | -11 | 26 | 0 |
| 30 Sep 15 | 245 | -4 | 23 | 0 |
| 30 Jun 15 | 242 | 1 | 21 | 0 |
| 31 Mar 15 | 242 | 1 | 20 | 0 |
| 31 Dec 14 | 223 | -1 | 19 | 0 |
| 30 Sep 14 | 204 | 1 | 19 | 0 |
| 30 Jun 14 | 182 | -2 | 19 | 0 |
| 31 Mar 14 | 161 | -3 | 20 | 0 |
| 31 Dec 13 | 152 | -1 | 20 | 0 |
| 30 Sep 13 | 134 | 0 | 20 | 0 |
| 30 Jun 13 | 118 | -1 | 20 | 0 |
Quality Earnings: N1A is currently unprofitable.
Growing Profit Margin: N1A is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: N1A is unprofitable, but has reduced losses over the past 5 years at a rate of 45% per year.
Accelerating Growth: Unable to compare N1A's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: N1A is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.6%).
Return on Equity
High ROE: N1A has a negative Return on Equity (-4.84%), as it is currently unprofitable.